NHBA antibodies elicited by 4CMenB vaccination are key for serum bactericidal activity against Neisseria gonorrhoeae

被引:0
|
作者
Tzeng, Yih-Ling [1 ]
Sannigrahi, Soma [1 ]
Stephens, David S. [1 ,2 ]
机构
[1] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA
关键词
SEXUALLY-TRANSMITTED INFECTIONS; FOR-DISEASE-CONTROL; B VACCINE; BINDING-PROTEIN; IMMUNITY; MENINGOCOCCUS; RESISTANCE;
D O I
10.1038/s41541-024-01018-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The 4CMenB (Bexsero(R)) vaccine contains detergent-extracted outer membrane vesicles (OMVs) from a Neisseria meningitidis (Nm) group B strain NZ98/254 and three recombinant Nm protein antigens: Neisseria adhesin A (NadA), Factor H binding protein (FHbp, as the C-terminal protein in the GNA2091-FHbp fusion), and Neisserial Heparin Binding Antigen (NHBA, as the N-terminal protein in the NHBA-GNA1030 fusion). Previous work has shown that 4CMenB generates serum antibodies to Nm and Neisseria gonorrhoeae (Ng) OMV proteins and lipooligosaccharide (LOS). Mounting evidence indicates 4CMenB can partially protect against mucosal infections with Ng. The immunologic basis for Ng cross protection remains to be fully elucidated. Ten paired human sera obtained pre- and post-immunization with 4CMenB (1 month after a third vaccine dose) were used in ELISAs and in Western blots to determine IgG and IgA serum responses to OMVs from Nm strain NZ98/254 (OMVNm) and two Ng strains, 1291 and CNG20 (OMVNg), and gonococcal recombinant NHBA (rNHBA(Ng)) proteins. Post 4CMenB sera, but not pre-sera, showed strong IgG and variable IgA responses to the OMVNm but lower (2-11-fold difference in signal intensity) recognition of OMVNg. All post (not pre) 4CMenB sera showed strong IgG, but variable IgA, recognition of rNHBA(Ng) by ELISAs and Western blots. Three post 4CMenB sera at 10% (v/v) concentration had serum bactericidal activity (SBA) against Ng strains 1291 and CNG20 (similar to 30-40% killing), not seen in paired pre-sera. These data confirmed 4CMenB-induced cross-reactive functional antibody responses to Ng. In competitive SBA assays, in which sera were pre-incubated with rNHBA, minimal SBA against Nm strain NZ98/254 was titrated away. However, most of the SBA against Ng strains 1291 and CNG20 required NHBA-specific antibodies, and the Delta nhba mutants were resistant to killing by post 4CMenB sera. Removing NHBA-specific and LOS-specific OMV antibodies simultaneously decreased SBA significantly more than the sum of removing individual antibodies alone, suggesting synergy between anti-NHBA and anti-OMV antibodies. Anti- NHBA(Nm) antibodies induced by 4CMenB vaccination cross react with NHBA(Ng) and substantially contribute to the bactericidal response toward Ng induced by the vaccine.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] BACTERICIDAL ANTIBODIES AGAINST NEISSERIA-GONORRHOEAE ELICITED BY NEISSERIA-MENINGITIDIS
    CREMIEUX, AC
    PUISSANT, A
    ANCELLE, R
    MARTIN, PMV
    LANCET, 1984, 2 (8408): : 930 - 930
  • [2] Evaluating vaccine-elicited antibody activities against Neisseria gonorrhoeae: cross-protective responses elicited by the 4CMenB meningococcal vaccine
    Gray, Mary C.
    Thomas, Keena S.
    Lamb, Evan R.
    Werner, Lacie M.
    Connolly, Kristie L.
    Jerse, Ann E.
    Criss, Alison K.
    INFECTION AND IMMUNITY, 2023,
  • [3] The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study
    Looker, Katharine J. J.
    Booton, Ross
    Begum, Najida
    Beck, Ekkehard
    Shen, Jing
    Turner, Katherine M. E.
    Christensen, Hannah
    BMC PUBLIC HEALTH, 2023, 23 (01)
  • [4] The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study
    Katharine J. Looker
    Ross Booton
    Najida Begum
    Ekkehard Beck
    Jing Shen
    Katherine M. E. Turner
    Hannah Christensen
    BMC Public Health, 23
  • [5] 4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents
    Biolchi, Alessia
    Tomei, Sara
    Brunelli, Brunella
    Giuliani, Maria
    Bambini, Stefania
    Borrow, Ray
    Claus, Heike
    Gorla, Maria Cecilia O.
    Hong, Eva
    Lemos, Ana Paula S.
    Lucidarme, Jay
    Taha, Muhamed-Kheir
    Vogel, Ulrich
    Budroni, Sonia
    Giuliani, Marzia M.
    Rappuoli, Rino
    Boucher, Philip
    Pizza, Mariagrazia
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (01) : 307 - 316
  • [6] 4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents
    Alessia Biolchi
    Sara Tomei
    Brunella Brunelli
    Maria Giuliani
    Stefania Bambini
    Ray Borrow
    Heike Claus
    Maria Cecilia O. Gorla
    Eva Hong
    Ana Paula S. Lemos
    Jay Lucidarme
    Muhamed-Kheir Taha
    Ulrich Vogel
    Sonia Budroni
    Marzia M. Giuliani
    Rino Rappuoli
    Philip Boucher
    Mariagrazia Pizza
    Infectious Diseases and Therapy, 2021, 10 : 307 - 316
  • [7] Awareness, knowledge and readiness of clinicians to deliver 4CMenB vaccines for Neisseria gonorrhoeae prevention
    Rabuszko, Lucy
    Stuart-George, Sarah
    Williams, Deborah
    Richardson, Daniel
    INTERNATIONAL JOURNAL OF STD & AIDS, 2025, 36 (03) : 255 - 256
  • [8] Synergistic activity of antibodies in the multicomponent 4CMenB vaccine
    Viviani, Viola
    Biolchi, Alessia
    Pizza, Mariagrazia
    EXPERT REVIEW OF VACCINES, 2022, 21 (05) : 645 - 658
  • [9] Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae
    Hadad, Ronza
    Jacobsson, Susanne
    Pizza, Mariagrazia
    Rappuoli, Rino
    Fredlund, Hans
    Olcen, Per
    Unemo, Magnus
    APMIS, 2012, 120 (09) : 750 - 760
  • [10] The Neisseria gonorrhoeae Vaccine Candidate NHBA Elicits Antibodies That Are Bactericidal, Opsonophagocytic and That Reduce Gonococcal Adherence to Epithelial Cells
    Semchenko, Evgeny A.
    Day, Christopher J.
    Seib, Kate L.
    VACCINES, 2020, 8 (02)